Report Detail
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth (Status and Outlook) 2019-2024
- RnM2837703 |
- 29 January, 2019 |
- Global |
- 116 Pages |
- LPI(LP Information) |
- Other
According to this study, over the next five years the Duchenne Muscular Dystrophy (DMD) Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Duchenne Muscular Dystrophy (DMD) Therapeutics business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Duchenne Muscular Dystrophy (DMD) Therapeutics market by product type, application, key companies and key regions.
This study considers the Duchenne Muscular Dystrophy (DMD) Therapeutics value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Pain Management Drugs
Corticosteroids
Deflazacort
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospitals
Clinics
Home Care
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bristol-Myers Squibb
FibroGen
Italfarmaco
Marathon Pharmaceuticals
NS Pharma
PTC Therapeutics
Pfizer
ReveraGen BioPharma
Santhera Pharmaceuticals
Sarepta Therapeutics
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Duchenne Muscular Dystrophy (DMD) Therapeutics market by identifying its various subsegments.
Focuses on the key global Duchenne Muscular Dystrophy (DMD) Therapeutics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Duchenne Muscular Dystrophy (DMD) Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Duchenne Muscular Dystrophy (DMD) Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report (Status and Outlook)
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size 2014-2024
- 2.1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size CAGR by Region
- 2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type
- 2.2.1 Pain Management Drugs
- 2.2.2 Corticosteroids
- 2.2.3 Prednisone
- 2.2.4 Deflazacort
- 2.2.5 Others
- 2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
- 2.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (2014-2019)
- 2.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application
- 2.4.1 Hospitals
- 2.4.2 Clinics
- 2.4.3 Home Care
- 2.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
- 2.5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application (2014-2019)
3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Players
- 3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Players
- 3.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Players (2017-2019)
- 3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Players (2017-2019)
- 3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Duchenne Muscular Dystrophy (DMD) Therapeutics by Regions
- 4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Regions
- 4.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth
- 4.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth
- 4.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth
- 4.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth
5 Americas
- 5.1 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Countries
- 5.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
- 5.3 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Countries
- 6.2 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
- 6.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics by Countries
- 7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
- 7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics by Countries
- 8.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
- 8.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
- 10.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast (2019-2024)
- 10.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Regions
- 10.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
- 10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
- 10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
- 10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
- 10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
- 10.7 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Type
- 10.8 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Application
11 Key Players Analysis
- 11.1 Bristol-Myers Squibb
- 11.1.1 Company Details
- 11.1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.1.4 Main Business Overview
- 11.1.5 Bristol-Myers Squibb News
- 11.2 FibroGen
- 11.2.1 Company Details
- 11.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.2.3 FibroGen Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.2.4 Main Business Overview
- 11.2.5 FibroGen News
- 11.3 Italfarmaco
- 11.3.1 Company Details
- 11.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.3.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.3.4 Main Business Overview
- 11.3.5 Italfarmaco News
- 11.4 Marathon Pharmaceuticals
- 11.4.1 Company Details
- 11.4.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.4.3 Marathon Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.4.4 Main Business Overview
- 11.4.5 Marathon Pharmaceuticals News
- 11.5 NS Pharma
- 11.5.1 Company Details
- 11.5.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.5.3 NS Pharma Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.5.4 Main Business Overview
- 11.5.5 NS Pharma News
- 11.6 PTC Therapeutics
- 11.6.1 Company Details
- 11.6.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.6.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.6.4 Main Business Overview
- 11.6.5 PTC Therapeutics News
- 11.7 Pfizer
- 11.7.1 Company Details
- 11.7.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.7.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.7.4 Main Business Overview
- 11.7.5 Pfizer News
- 11.8 ReveraGen BioPharma
- 11.8.1 Company Details
- 11.8.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.8.3 ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.8.4 Main Business Overview
- 11.8.5 ReveraGen BioPharma News
- 11.9 Santhera Pharmaceuticals
- 11.9.1 Company Details
- 11.9.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.9.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.9.4 Main Business Overview
- 11.9.5 Santhera Pharmaceuticals News
- 11.10 Sarepta Therapeutics
- 11.10.1 Company Details
- 11.10.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
- 11.10.4 Main Business Overview
- 11.10.5 Sarepta Therapeutics News
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Duchenne Muscular Dystrophy (DMD) Therapeutics . Industry analysis & Market Report on Duchenne Muscular Dystrophy (DMD) Therapeutics is a syndicated market report, published as Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth (Status and Outlook) 2019-2024. It is complete Research Study and Industry Analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
